Multidrug-resistant (MDR) bacteria constitute a global health issue. Over the past ten years, interest in nanoparticles, particularly metallic ones, has grown as potential antibacterial candidates. However, as there is no consensus about the procedure to characterize the metallic nanoparticles (MNPs; i.e., metallic aggregates) and evaluate their antibacterial activity, it is impossible to conclude about their real effectiveness as a new antibacterial agent. To give part of the answer to this question, 12 nm gold and silver nanoparticles have been prepared by a chemical approach. After their characterization by transmission electronic microscopy (TEM), Dynamic Light Scattering (DLS), and UltraViolet-visible (UV-vis) spectroscopy, their surface accessibility was tested through the catalytic reduction of the 4-nitrophenol, and their stability in bacterial culture medium was studied. Finally, the antibacterial activities of 12 nm gold and silver nanoparticles facing Staphylococcus aureus and Escherichia coli have been evaluated using the broth microdilution method. The results show that gold nanoparticles have a weak antibacterial activity (i.e., slight inhibition of bacterial growth) against the two bacteria tested. In contrast, silver nanoparticles have no activity on S. aureus but demonstrate a high antibacterial activity against Escherichia coli, with a minimum inhibitory concentration of 128 µmol/L. This high antibacterial activity is also maintained against two MDR-E. coli strains.

Due to the constant increase in the number of infectious diseases and the concomitant lack of treatment available, metallic nanoparticles (e.g., silver nanoparticles) have been of particular interest in the last decades. Indeed, several studies suggest that silver nanoparticles have valuable antimicrobial activities, especially against bacteria, which may lead us to think that these nanoparticles may one day be an attractive therapeutic option for the treatment of bacterial infections. Unfortunately, when we look a little closer to these studies, we can see a very great heterogeneity (e.g., in the study design, in the synthetic process of nanoparticles, in the methods that explore the antibacterial properties of nanoparticles and in the bacteria chosen) making cross-interpretation between these studies impossible, and significantly limiting the interest of silver nanoparticles as promising antibacterial agents. We have selected forty-nine international publications published since 2015, and propose to discuss, not the results obtained, but precisely the different methodologies developed in these publications. Through this discussion, we highlighted the aspects to improve, or at least to homogenize, in order to definitively establish the interest of silver nanoparticles as valuable antibacterial agents.